Filter By Category
Archives
Share on -
DOVRAMILAST
Generic Name: DOVRAMILAST
ABSTRACT -
Dovramilast is an investigational small-molecule phosphodiesterase-4 inhibitor being studied for inflammatory and immunologic diseases. It is not a prescribing guide.
DOSAGE -
- No routine clinical dosage is established for general use.
- Clinical-trial dose, titration, food instructions, and dose modifications must be followed.
- Monitor tolerability carefully because PDE4 inhibitors commonly cause gastrointestinal effects.
SIDE EEFECTS -
- Nausea, diarrhea, vomiting, abdominal pain, headache, insomnia, or weight loss may occur.
- Mood changes or depression-like symptoms are class concerns for some PDE4 inhibitors.
- Laboratory or vital-sign changes may occur in clinical studies.
ALLERGIC REACTIONS -
- Immediate rash, hives, itching, flushing, or generalized skin reaction
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, shortness of breath, or severe dizziness
- Severe hypotension, collapse, or anaphylaxis requires emergency care
- Any suspected allergy should be documented and reported to future healthcare providers
DRUG INTERACTIONS-
- CYP enzyme inducers or inhibitors may alter exposure depending on metabolism.
- Other immunomodulators may increase infection or tolerability concerns.
- Patients should report all medicines and supplements.
PREAUTONS–
- Assess psychiatric history, weight, gastrointestinal disease, pregnancy, and hepatic/renal function.
- Monitor mood, weight, GI tolerance, infection symptoms, and adherence.
- Use only according to protocol or approved label.
WARNINGS –
- Severe depression, suicidal ideation, persistent vomiting/diarrhea, or allergic symptoms require urgent medical attention.
- Investigational efficacy and safety are not fully established.
- Keep out of reach of children.
Share on -
. Developed by